Harnessing the immune system for treatment and detection of tau pathology

Journal of Alzheimer's Disease

Volumn 40, Issue S1, 2014, Pages

  Congdon, Erin E ^a   Krishnaswamy, Senthilkumar ^a   Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; imaging; immunotherapy; tau

Indexed keywords

AMYLOID; ANTIBODY; LIGAND; TAU PROTEIN;

ANTIGEN BINDING; ARTICLE; CELL PHAGOCYTOSIS; ENDOSOME; EXPERIMENTAL MODEL; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LYSOSOME; MICROGLIA; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; NEUROPATHOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; TAUOPATHY; ALZHEIMER DISEASE; ANIMAL; BRAIN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; PHOSPHORYLATION; TAU PROTEINS;

EID: 84901811175     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132435     Document Type: Article

References (102)

1. Schenk D, Barbour R, DunnW, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I,Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C,Walker S,Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. (Pubitemid 29327547)
2. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94, 4109-4112. (Pubitemid 27180507)
3. Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 93, 452-455. (Pubitemid 26038175)
4. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23, 8532-8538. (Pubitemid 37158753)
5. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982. (Pubitemid 32101644)
6. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, HancockWW,Weiner HL, Selkoe DJ (2000) Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 920, 328-331. (Pubitemid 32056589)
7. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G,Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, ArendashGW(2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985. (Pubitemid 32101645)
8. Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 3, 824-828. (Pubitemid 135706694)
9. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, Team ANS (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. (Pubitemid 40617691)
10. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120, 369-384.
11. Callaway E (2012) Alzheimer's drugs take a new tack. Nature 489, 13-14.
12. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA (2010) Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 120, 13-20.
13. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14, 11-20. (Pubitemid 38200585)
14. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131. (Pubitemid 40082949)
15. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, WellerRO(2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 9, 448-452. (Pubitemid 36460079)
16. Serrano-Pozo A,William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT (2010) Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133, 1312-1327.
17. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
18. Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG (2013) Bapineuzumab alters abeta composition: Implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS One 8, e59735.
19. Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ, Zajac JJ, Talbot JA, Jensen HF, Sethuraman G, Demattos RB, May PC, Dean RA (2011) Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. J Alzheimers Dis 26, 531-541.
20. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P, Members EUCTF (2013) Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: Areport from the EU/US/CTADTask Force. Alzheimers Dement 9, 438-444.
21. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial I (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
22. Streffer J, Blennow K, Salloway S, Zetterberg H, Xu Y, Lu Y, Lull J, Collins P, Tudor JC, Gregg K, Styren S, Yuen E, Grundman M, Brasher RH, Liu E (2013) Effect of bapineuzumab on CSF p-tau and t-tau in mild-to-moderate Alzheimer's disease: Results from two phase III trials in APOE-4 carriers and noncarriers. Alzheimer Dement 9, P138.
23. Asuni AA, Boutajangout A, Quartermain D, SigurdssonEM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115-9129. (Pubitemid 47312068)
24. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30, 16559-16566.
25. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6, e26860.
26. Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, Lopez-Deber MP, Reis P, Hickman DT, Adolfsson O, Chuard N, Ndao DM, Borghgraef P, Devijver H, Van Leuven F, Pfeifer A, Muhs A (2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS One 8, e72301.
27. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224, 472-485.
28. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: Asuitable therapeutic approach. Curr Alzheimer Res 9, 397-405.
29. Krishnamurthy P, Sait HBR, Boutajangout A, Sigurdsson EM(2009) Immunotherapy targeting Alzheimer's phosphotau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a mouse model of tauopathy. Alzheimers Dement 5, P112.
30. Boutajangout A, Sait HB, Gonzalez V, Sigurdsson EM (2011) Targeting hyperphosphorylated tau protein with a monoclonal antibody at an advanced stage of tau pathology improves congition in a mouse model. Alzheimers Dement 7, S480-S481.
31. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118, 658-667.
32. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M (2011) Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J Biol Chem 286, 34457-34467.
33. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2010) Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy. Alzheimers Dement 6, S578.
34. d'Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS One 8, e62402.
35. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287, 19440-19451.
36. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE,Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414.
37. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697.
38. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7, e31302.
39. Hochgrafe K, Sydow A, Mandelkow EM (2013) Regulatable transgenic mouse models of Alzheimer disease: Onset, reversibility and spreading of Tau pathology. FEBS J 280, 4371-4381.
40. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A,WinklerDT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 110, 9535-9540.
41. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11, 909-913.
42. Clavaguera F, Grueninger F, Tolnay M (2014) Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. Neuropharmacology 76 Pt A 9-15.
43. Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11, 155-159.
44. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284, 12845-12852.
45. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 33, 1024-1037.
46. Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF (2010) Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis 19, 647-664.
47. Mohamed NV, Herrou T, Plouffe V, Piperno N, Leclerc N (2013) Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission. Eur J Neurosci 37, 1939-1948.
48. Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 6, 446-450.
49. Congdon EE, Gu J, Sait HB, Sigurdsson EM (2013) Antibody uptake into neurons occurs primarily via clathrin dependent Fcgamma receptor endocytosis, and is a prerequisite for acute tau clearance. J Biol Chem 288, 35452-35465.
50. Gruniger F, Collin L, Oroszian-Szovik K, Schraemi M, Mundigl O, Goepfert U, Bohrman B (2012) Reduction in phosphorylated tau aggregates in TauPS2APP transgenic mice by passive immunotherapy with an anti-tau/pS422 antibody. Alzheimers Dement 8, P573.
51. Gu J, Congdon EE, Sigurdsson EM (2013) Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau pathology. J Biol Chem 288, 33081-33095.
52. Krishnamurthy PK, Deng Y, Sigurdsson EM (2011) Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry 2, 59.
53. Shamir DB, Rosenqvist N, Gregory MD, Rasool S, Pedersen JT, Sigurdsson EM (2013) Uptake of tau antibodies and paired helical filament enriched tau protein in naive and transfected human neuroblastoma cells. Soc Neurosci Abstr, Program No. 524.05.
54. Gros-Louis F, Soucy G, Lariviere R, Julien JP (2010) Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 113, 1188-1199.
55. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868. (Pubitemid 40805347)
56. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6, e19338.
57. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK (2007) Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 282, 18895-18906. (Pubitemid 47100144)
58. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63, 1459-1467. (Pubitemid 44547559)
59. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248, 451-456.
60. Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, Frangione B, Wisniewski T, SigurdssonEM( 2006)Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci 24, 2530-2542. (Pubitemid 44726765)
61. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM (2011) Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 6, e18296.
62. Esquerda-Canals G, Marti J, Rivera-Hernandez G, Gimenez-Llort L, Villegas S (2013) Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid beta antibody fragment. MAbs 5, 660-664.
63. Gimenez-Llort L, Rivera-Hernandez G, Marin-Argany M, Sanchez-Quesada JL,Villegas S (2013) Early intervention in the 3xTg-AD mice with an amyloid beta-antibody fragment ameliorates first hallmarks of Alzheimer disease. MAbs 5, 665-677.
64. NisbetRM,Nigro J, BreheneyK, Caine J, HattarkiMK,Nuttall SD (2013) Central amyloid-beta-specific single chain variable fragment ameliorates Abeta aggregation and neurotoxicity. Protein Eng Des Sel 26, 571-580.
65. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61, 797-805. (Pubitemid 35001352)
66. Schmidt ML, Schuck T, Sheridan S, Kung MP, Kung H, Zhuang ZP, Bergeron C, Lamarche JS, Skovronsky D, Giasson BI, Lee VM, Trojanowski JQ (2001) The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3- hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol 159, 937-943. (Pubitemid 32847184)
67. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319. (Pubitemid 38269583)
68. Nelissen N, Van Laere K, Thurfjell L, Owenius R, VandenbulckeM, Koole M, Bormans G, Brooks DJ, Vandenberghe R(2009) Phase 1 study of the Pittsburgh compoundBderivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50, 1251-1259.
69. Nyberg S, Jonhagen ME, Cselenyi Z, Halldin C, Julin P, Olsson H, Freund-Levi Y, Andersson J, Varnas K, Svensson S, Farde L (2009) Detection of amyloid in Alzheimer's disease with positron emission tomography using [C]AZD2184. Eur J Nucl Med Mol Imaging 36, 1859-1863.
70. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, Group AAS (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
71. Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM (2011) Florbetapir f-18: A histopathologically validated Beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 41, 300-304.
72. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL (2008) Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7, 129-135.
73. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11 C]SB-13 PET. Am J Geriatr Psychiatry 12, 584-595. (Pubitemid 41031060)
74. Cui M, Ono M, Kimura H, Kawashima H, Liu BL, Saji H (2011) Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of beta-amyloid plaques in Alzheimer's disease. Nucl Med Biol 38, 313-320.
75. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48, 553-561. (Pubitemid 47571409)
76. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, KlunkWE,Price J,DeKosky S,Wester HJ, Schwaiger M,KurzA(2008) Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39, 619-633. (Pubitemid 350117638)
77. Pike KE, Savage G,Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844. (Pubitemid 350033975)
78. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106, 6820-6825.
79. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, Krautkramer MJ, Kung HF, Skovronsky DM, Hefti F, ClarkCM(2012) Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 26, 8-16.
80. Saint-Aubert L, Barbeau EJ, Peran P, Nemmi F, Vervueren C, Mirabel H, Payoux P, Hitzel A, Bonneville F, Gramada R, Tafani M, Vincent C, Puel M, Dechaumont S, Chollet F, Pariente J (2013) Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res 3, 43.
81. Teipel S, Heinsen H, Amaro E Jr, Grinberg LT, Krause B, Grothe M, Alzheimer's Disease Neuroimaging I (2013) Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging 35, 482-491.
82. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, PontecorvoMJ (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51, 913-920.
83. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O, Florbetaben Study G (2011) Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 10, 424-435.
84. Barthel H, SabriO(2011) Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET. J Alzheimers Dis 26(Suppl 3), 117-121.
85. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselenyi Z, Masters CL,Villemagne VL (2013) Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med 54, 880-886.
86. FDA Press Announcements, FDA approves second brain imaging drug to help evaluate patients for Alzheimer's disease, dementia, http://www.fda.gov/ NewsEvents/News room/PressAnnouncements/ucm372261.htm, October 25, 2013.
87. Hintersteiner M, Enz A, Frey P, Jaton AL, KinzyW, Kneuer R, Neumann U, Rudin M, Staufenbiel M, Stoeckli M, Wiederhold KH, Gremlich HU (2005) In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 23, 577-583. (Pubitemid 41724896)
88. Jensen JR, Cisek K, Funk KE, Naphade S, Schafer KN, Kuret J (2011) Research towards tau imaging. J Alzheimers Dis 26(Suppl 3), 147-157.
89. Jensen JR, Cisek K, Honson NS, Kuret J (2011) Ligand polarizability contributes to tau fibril binding affinity. Bioorg Med Chem 19, 5147-5154.
90. Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Fujiwara H, Nemoto M, Maruyama M, Arai H, Yanai K, Sawada T, Kudo Y (2005) Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25, 10857-10862. (Pubitemid 41692615)
91. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL (2011) 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134, 1089-1100.
92. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, Yoshikawa T, Arai H, Iwata R, Kudo Y, Yanai K (2013) Comparison of the binding characteristics of [F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 40, 125-132.
93. Alzheimer's Research Forum, Tau Tracers Shine at Boston Conference, http://www.alzforum.org/new/detail.asp?id= 3561, Last updated July 31, 2013.
94. Ono M, Hayashi S, Matsumura K, Kimura H, Okamoto Y, Ihara M, Takahashi R, Mori H, Saji H (2011) Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. ACS Chem Neurosci 2, 269-275.
95. Harada R, Okamura N, Furumoto S, Yoshikawa T, Arai H, Yanai K, Kudo Y (2013) Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer's disease brain. Mol Imaging Biol 16, 19-27.
96. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Su H, Szardenings AK, Walsh JC, Wang E, Yu C, Zhang W, Zhao T, Kolb HC (2013) [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 6, 666-676.
97. ZhangW, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31, 601-612.
98. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC(2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34, 457-468.
99. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38, 171-184.
100. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108.
101. Tian H, Davidowitz E, Moe J, Sierks M (2012) Single chain variable fragment specific for trimeric tau as a tool to study Alzheimer's disease. Soc Neurosci Abstr, Program No. 437.04.
102. Krishnaswamy S, Rajamohamedsait WJ, Lin Y, Rajamohamedsait HB, Krishnamurthy PK, Sigurdsson EM (2013) Tau antibody single chain variable fragments as potential therapy and/or diagnostic marker for Alzheimer's disease and related tauopathies. Soc Neurosci Abstr, Program No. 63.05.